Glaxo to take full control of Cellzome

Drugs giant GlaxoSmithKline is to take full control of Cellzome, a company specialising in the study of protein structures and functions.

Glaxo, which currently owns just under one fifth of Cambridge-based Cellzome, is paying £61m in cash to buy up the rest of the company, which will become part of Glaxo's research and development (R&D) organisation.

Cellzome's proteomics technologies can be used throughout the drug discovery process from screening to selectivity profiling of compounds in different cells and also in patient samples.

MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

The technologies that Cellzome has developed differ from other traditional methods used in early drug discovery by assessing drug interactions with target proteins in a setting which more closely represents that found in a whole biological system. This allows scientists the opportunity to observe how candidate drugs affect both intended and non-desired targets in a close-to-physiological environment and may pinpoint potential safety issues earlier in the process.

Glaxo and Cellzome have two active early stage research collaborations using these discovery capabilities within the immune-inflammation therapy area.

Simultaneous with the acquisition, Cellzome shareholders, including Glaxo, intend to create a spin-off company, which would hold the rights to certain of Cellzome's assets and activities that Glaxo does not want as part of its drugs development pipeline.

JH